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Objectives. Cardiovascular mortality in patients with chronic critical lower limb ischaemia (CCLI) is high and early risk
stratification in these patients may aid clinical management improving outcomes. Cardiac troponin I (cTnI) has prognostic
significance in patients with unstable angina. The aim of this study was to evaluate the prognostic significance of cardiac
troponins in CCLI patients who had no clinical evidence of unstable coronary heart disease.
Methods. Patients (n¼ 152) admitted with CCLI to a single vascular unit over a two-year period were included prospec-
tively in this study. Patients with clinical evidence of unstable coronary disease were excluded from the study. Patient
demographics, clinical history, co-morbidity and risk factors for peripheral vascular disease were documented. Admission
cTnI levels were recorded using a threshold, 0.1 ng/ml. The primary endpoint was mortality.
Results. Fifty-two patients (34.2%) had an elevated cTnI, whilst 100 (65.8%) had cTnI <0.1 ng/ml. Sixty-two patients
died during the follow-up period, 38 with an elevated admission cTnI. Death rate in patients with cTnI>0.1 ng/nl was 73%
compared with 24% in those with levels below the threshold (p< 0.0001). Patients with elevated cTnI were significantly
older than those with normal level (median age 76 years vs 71 years, p< 0.001). An elevated cTnI was found to indepen-
dently predict disease-specific mortality on Cox regression analysis (Hazard Ratio 4.2; 95% Confidence Interval 1.3e12.7).
Conclusion. In this series of patients with CCLI the measurement of cTnI on admission was a significant independent
predictor of survival. cTnI has potential as a prognostic test to stratify patients with a high cardiovascular risk and
may enable further optimisation of these high-risk patients.
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Patients with Chronic Critical Limb Ischaemia (CLLI)
usually have advanced multi-focal atherosclerosis.
Therefore, it is not surprising to find a high incidence
of coronary heart disease, congestive heart failure and
cardiac valve disease in patients with CLLI.1,2 An au-
topsy study has shown that >90% of vascular patients
have advanced coronary atherosclerosis.3 The 1 year
mortality rate for patients with CCLI has been
reported to be 26%, and 75% at 10 years.1,4
Cardiac troponins (cTn) are well established as spe-
cific prognostic tools for patients with acute coronary
syndromes (ACS). Troponin I is part of the troponine
tropomyosin complex along with troponins C and T.
With myocardial necrosis, the troponins exhibit a
biphasic release pattern due to the release of both
free cytosolic and structurally bound molecules.
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makes it an important prognostic indicator in patients
presenting with chest pain.5 More recently serum cTnI
measurement in patients with chronic renal failure6
predicted survival and routine monitoring of post-
operative cTnI levels following vascular surgery 7e10
was shown to correlate well with medium and long-
term all-cause and cardiac mortality. Peri-operative
myocardial injury, as demonstrated by an elevated
cTnI, has also been shown to be present in at least
one third of CCLI patients operated on.11
In order to improve post-operative outcome in vas-
cular patients, the American College of Cardiology/
American Heart Association (ACC/AHA) developed
guidelines for pre-operative cardiac risk evaluation.12
Despite pre-operative risk stratification with these
guidelines, vascular patients still remain at a high
risk of cardiac related morbidity and mortality.13 The
aim of this study was to evaluate the prognostic value
of cTnI measurement, taken at the time of admission,
in CCLI patients who had no clinical evidence of
unstable coronary heart disease.erved.
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Patients
All patients admitted to a university teaching hospital
with chronic critical limb ischaemia14 were entered
into this prospective study over a two year period.
Demographic data, comorbidities and relevant drug
history were recorded at the time of admission to
the study. Any subsequent surgical or radiological in-
tervention also was documented as either primary
surgery (limb-salvage), primary surgery (amputa-
tion), radiological or a combined procedure. Patients
with evidence of acute limb ischaemia, current symp-
tomatic or unstable coronary disease were excluded.
The primary endpoint of the study was all-cause mor-
tality. The secondary endpoint was cardiac specific
mortality (myocardial infarction (MI), arrhythmias,
congestive cardiac failure (CCF)).
Measurement of troponin
Admission cTnI levels were analysed in venous
blood. Determination of serum cTnI was performed
on the ACS:Centaur analyzer (Bayer Diagnostics,
Tarrytown, NY) using a two step chemiluminescence
assay. The total coefficient of variance of the assay
was <10% and the limit of detection was 0.1 ng/ml.
A level >0.1 ng/ml was considered positive for myo-
cardial necrosis.
Follow up
Patients were followed up in outpatient clinics follow-
ing discharge. For patients who died in hospital, hos-
pital records and autopsy results were retrieved and
reviewed. Mortality was recorded from the hospital
Patient Administration System. For patients who
died in the community, general practitioners were
approached to ascertain the cause of death. Cardiac
specific mortality was recorded from the death certifi-
cate and by reviewing the hospital notes.
Statistical analysis
Analysis was performed using SPSS version 11.0.0
(Statistical package for Social Sciences Inc, Chicago,
Illinois, USA). c2 test was used to perform univariate
analysis for categorical variables and Mann-Whitney
U test for continuous variables. Results are presented
as median with interquartile range unless otherwise
specified. Cox regression analysis of significant vari-
ables was conducted. Differences in the Kaplan-Meier
survival curves were compared using the log-rankEur J Vasc Endovasc Surg Vol 33, June 2007test. A p value  0.05 was considered statistically
significant.
Results
One hundred and fifty-two patients (97 men and 55
women) met the inclusion criteria for analysis during
the study period. The median age was 72 (IQR 65.7e
81 years) and median follow up was 8.7 months (IQR
3.1e16 months). For analysis, patients were grouped
into those with a cTnI <0.1 and >0.1 ng/ml.
Fifty-two (34.2%) patients had an elevated cTnI
(0.1 ng/ml) on admission. Age, gender, a history of
renal failure, previous stroke, hypertension, statin
therapy, diabetes, previous MI/CCF and surgical or
radiological intervention were assessed. Baseline
characteristics of both groups are shown in Table 1.
Patients with elevated cTnI were significantly older
than those with normal level (median age 76 years
vs 71 years, p<0.001). The incidence of chronic ob-
structive lung disease (COPD) was higher in patients
with an elevated cTnI.
Sixty-two patients died during the follow-up period
and their details are presented in Table 2. Thirty-eight
of these had an elevated cTnI at entry into the study.
Kaplan-Meier survival analysis is shown in Fig. 1,
using a threshold of 0.1 ng/ml for cTnI. A significant
difference in survival time for all cause mortality was
noted between the two cTnI groups (c2¼ 8.6, df¼ 1,
p¼ 0.0001). Comparing the two groups for cardiac spe-
cific mortality a significant difference in survival was
again noted (c2¼ 5.4, df¼ 1, p¼ 0.002) (Fig. 2).
Logistic regression analysis of troponin showed no
relation with age, smoking, hypertension, chronic re-
nal failure, COPD or a previous history of a MI,
CCF or diabetes. However, an elevated cTnI was
found to independently predict disease-specific mor-
tality (Hazard Ratio 4.2; 95% Confidence Interval
1.3e12.7).
Table 1. Baseline characteristics of risk factors
cTnI <0.1
(n¼ 100)
cTnI >0.1
(n¼ 52)
p value
Age (IQR) years 71 (61e83) 76 (71e86) 0.001
Smoker 70 35 0.82
Diabetes Mellitus 34 11 0.08
Hypertension 57 29 0.56
Myocardial Infarction 9 6 0.58
Stroke 9 6 0.58
Chronic renal failure 2 4 0.1
Statin 26 14 0.8
Congestive cardiac failure 3 5 0.08
COPD 1 4 0.04
(IQR-Interquartile range, COPD-Chronic Obstructive Airways
Disease).
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pass surgery, 38 a radiological procedure, and 35 were
treated conservatively, the details of the interventions
are shown in Table 3. Four of the patients on admis-
sion had serum troponin levels >7 ng/ml, none had
a history of chest pain, 3 were known diabetics. All
patients were referred to a cardiologist, 3 had ECG
evidence of a recent MI and one was diagnosed
with viral myocarditis: as a result of these findings
they were treated conservatively.
Discussion
In the year 2000, the European Society of Cardiology
and the American College of Cardiology Committee
jointly redefined myocardial infarction (MI) by an ele-
vation of cardiac troponin T (cTnT) or I (cTnI) in con-
junction with clinical evidence of myocardial
ischaemia.5 Since then, cTnT and cTnI have replaced
creatine kinase-MB (CK-MB) as the preferred bio-
chemical markers for the diagnosis of MI. An elevation
of cTn indicates the presence of, but not the underlying
Table 2. Causes of death in patients with high and low cTnI
measurements
Cause of death cTnI <0.1 cTnI >0.1
Cardiac arrest/MI/CCF 9 18
Sepsis/Multi-Organ Failure 6 4
Pneumonia 4 9
Renal Failure 1 2
Old age 2 e
Not known 1 2
Cancer 1 2
Other 1 (GI bleed)
(GI-Gastrointestinal).
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Fig. 1. Kaplan-Meier of all-cause mortality related to a nor-
mal ( ) and elevated cTn (———) (p< 0.001).reason for, myocardial injury. Hence, besides acute
myocardial infarction (AMI), there are a number of po-
tential diseases with troponin release. These include
acute pulmonary embolism, heart failure, myocarditis,
sepsis and end stage renal disease.15e18
This study has shown that 34% of patients with
CCLI had an elevated cTn on admission, with no re-
cent history of chest pain or shortness of breath, indi-
cating that other mechanisms underlie these troponin
elevations. One reason for the release of cTn from
damaged myocardial cells could be small areas of
clinically silent myocardial necrosis, in this high risk
population. Other possible explanations might be an
oxygen supplyedemand mismatch of the myocar-
dium, since as a consequence of rest pain, the systemic
inflammatory response/sepsis inducing tachycardia
the oxygen demand of the myocardium is increased.
In addition, local and circulating inflammatory
markers including tumour necrosis factor-a, interleu-
kin 6 and reactive oxygen species, which are known
to be elevated in patients with CCLI, may lead to direct
myocardial injury by cytotoxic effects.19e22
Patients with CCLI are a group where cardiovascu-
lar risk factors are common and ischaemic heart dis-
ease deaths may already have removed those most
Follow up in months
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Fig. 2. Kaplan-Meier of cardiac specific mortality related to
a normal ( ) and elevated cTn (———) (p¼ 0.002).
Table 3. A comparison of intervention in patients with high and
low cTnL measurements
cTnI <0.1
(n¼ 100)
cTnI >0.1
(n¼ 52)
Surgery (non-amputation) 28 (5) 12 (5)
Angioplasty/stenting 25 (8) 13 (11)
Combined procedure 7 (2) 1 (1)
Amputation 13 (3) 8 (6)
Minor amputation þ
angioplasty/stent
9 (2) 1 (0)
Conservative 18 (6) 17 (13)
Mortality figures in parenthesis.Eur J Vasc Endovasc Surg Vol 33, June 2007
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able. This study of cTn measured on initial admission
shows cTnI to be predictive of all cause mortality and
its value is independent of age, previous cardiac his-
tory or diabetes. This is surprising given the high in-
cidence of ischaemic heart disease in the population.
Interestingly, it has been observed before in another
high risk group of haemodialysis patients.23 Recent
studies of patients with acute limb ischaemia and
major amputation also demonstrated that an elevated
cTn was a predictor of early outcome and associated
with a postoperative cardiac event, independent of
other comorbidity.24e25
This work is not without its limitations. The predic-
tive value of cTnI for cardiovascular death is less than
for all causemortality. A previous study of vascular pa-
tients showed thatmore than half of deaths recorded as
non-cardiac were actually cardiovascular in nature.26
Patients with recent ECG changes where excluded
from the study, and it would seem likely that excluding
this group would underestimate the cardiovascular
risk. The patient cohort studied has advanced vascular
disease, which increases the likelihood of coronary ar-
tery disease. It would be interesting to make a detailed
and accurate assessment of cardiovascular risk at an
earlier stage, broadening the scope for screening, risk
factor modification and intervention.
This study found that admission serum cTnI was a
significant predictor of subsequent mortality in CCLI
patients. The predominant cause of death was noted
to be cardiac in nature. The value of the cTnI test
held even when other significant cardiac risk factors
were considered. The clinical utility of the cTnI mea-
surement is two fold. First identification of patients
at high cardiac risk enables appropriate primary and
secondary preventive strategies to be implemented.27
Second realistic awareness of likely long-term prog-
nosis would be an invaluable tool when planning suit-
ability for surgical or radiological intervention.
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